Compare Charles River Laboratories Intl. Inc (CRL) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Raymond James Financial, Inc. — how do they compare? Charles River Laboratories Intl. Inc trades at $232.4 (market cap $11.14B), while Raymond James Financial, Inc. trades at $170.85 (market cap $32.63B). The key difference: Raymond James Financial, Inc. is far larger — about 2.9× Charles River Laboratories Intl. Inc's market cap, and Raymond James Financial, Inc. pays a 1.29% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | RJF | |
|---|---|---|
Market Cap | $11.14B | $32.63B |
Sector | Health | Financials |
52-Week High | $233.60 | $176.43 |
52-Week Low | $145.57 | $140.89 |
Enterprise Value | $14.00B | — |
Dividend Yield | — | 1.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Raymond James Financial (RJF) trades at $166.98, down 0.68% on the day, with a bullish technical outlook and strong fundamental performance. The stock shows consistent earnings beats, with Q1 2026 EPS of $2.83 surpassing expectations of $2.76, and revenue growth from $10.9B in 2022 to $13.84B in 2025. Analyst consensus is positive with a $176.83 price target, and recent news highlights momentum and dividend declarations.
The outlook for RJF remains favorable due to earnings momentum and analyst support, though risks include expense pressures and market volatility. Investment opportunity lies in its valuation below consensus target and dividend growth, but investors should monitor cost management and economic conditions that could impact financial services demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
